Skip to main content

Chakma Justin's Form 4 filing

ARS Pharmaceuticals, Inc. (SPRY) · filed Dec 4, 2024

Accession no.
0001415889-24-028351
Filed
Dec 4, 2024
Trade date
Dec 2-3, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.21M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Chakma JustinCIK 0001951238Officer (Chief Business Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2024Common StockMOption exerciseAcquired+45,000$0.84+$37,800181,380Direct
Dec 2, 2024Common StockSSaleDisposed−45,000$13.67−$615,150136,380Direct
Dec 3, 2024Common StockMOption exerciseAcquired+3,260$0.84+$2,738.4139,640Direct
Dec 3, 2024Common StockMOption exerciseAcquired+41,740$0.84+$35,061.6181,380Direct
Dec 3, 2024Common StockSSaleDisposed−45,000$13.19−$593,550136,380Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 2, 2024Common StockMOption exerciseDisposed−45,000$0.00$03,260Direct
Dec 3, 2024Common StockMOption exerciseDisposed−3,260$0.00$00Direct
Dec 3, 2024Common StockMOption exerciseDisposed−41,740$0.00$0194,640Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)